These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27131800)

  • 1. Neurocognitive, psychiatric, and substance use characteristics in opioid dependent adults.
    Arias F; Arnsten JH; Cunningham CO; Coulehan K; Batchelder A; Brisbane M; Segal K; Rivera-Mindt M
    Addict Behav; 2016 Sep; 60():137-43. PubMed ID: 27131800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.
    Scott TM; Arnsten J; Olsen JP; Arias F; Cunningham CO; Rivera Mindt M
    Addict Sci Clin Pract; 2021 Oct; 16(1):64. PubMed ID: 34689841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study.
    Scott TM; Rivera Mindt M; Cunningham CO; Arias F; Coulehan K; Mangalonzo A; Olsen P; Arnsten JH
    Subst Abuse Treat Prev Policy; 2017 Nov; 12(1):48. PubMed ID: 29141650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent effects of HIV infection and cocaine dependence on neurocognitive impairment in a community sample living in the southern United States.
    Meade CS; Towe SL; Skalski LM; Robertson KR
    Drug Alcohol Depend; 2015 Apr; 149():128-35. PubMed ID: 25697913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy.
    Tofighi B; Grossman E; Goldfeld KS; Williams AR; Rotrosen J; Lee JD
    Subst Use Misuse; 2015; 50(12):1571-8. PubMed ID: 26623697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Underrepresentation of diverse populations and clinical characterization in opioid agonist treatment research: A systematic review of the neurocognitive effects of buprenorphine and methadone treatment.
    Mindt MR; Coulehan K; Aghvinian M; Scott TM; Olsen JP; Cunningham CO; Arias F; Arnsten JH
    J Subst Abuse Treat; 2022 Apr; 135():108644. PubMed ID: 34857427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive functioning in patients maintained on buprenorphine at peak and trough buprenorphine levels: An experimental study.
    Singh A; Rao R; Chatterjee B; Mishra AK; Kaloiya G; Ambekar A
    Asian J Psychiatr; 2021 Jul; 61():102697. PubMed ID: 34030027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
    Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W
    Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment.
    Savant JD; Barry DT; Cutter CJ; Joy MT; Dinh A; Schottenfeld RS; Fiellin DA
    Drug Alcohol Depend; 2013 Jan; 127(1-3):243-7. PubMed ID: 22771144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients.
    Dunn KE; Finan PH; Andrew Tompkins D; Strain EC
    Addict Behav; 2018 Jan; 76():8-14. PubMed ID: 28735039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurocognitive profiles of marginally housed persons with comorbid substance dependence, viral infection, and psychiatric illness.
    Gicas KM; Vila-Rodriguez F; Paquet K; Barr AM; Procyshyn RM; Lang DJ; Smith GN; Baitz HA; Giesbrecht CJ; Montaner JS; Krajden M; Krausz M; MacEwan GW; Panenka WJ; Honer WG; Thornton AE
    J Clin Exp Neuropsychol; 2014; 36(10):1009-22. PubMed ID: 25380059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone.
    Barry DT; Savant JD; Beitel M; Cutter CJ; Moore BA; Schottenfeld RS; Fiellin DA
    J Addict Med; 2012 Dec; 6(4):274-9. PubMed ID: 23041680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resilience attenuates the association between neurocognitive functioning and everyday functioning in individuals aging with HIV in the Deep South.
    Fazeli PL; Moore RC; Vance DE
    Int J Geriatr Psychiatry; 2019 Jan; 34(1):72-78. PubMed ID: 30230608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of behavioral treatment conditions in buprenorphine maintenance.
    Ling W; Hillhouse M; Ang A; Jenkins J; Fahey J
    Addiction; 2013 Oct; 108(10):1788-98. PubMed ID: 23734858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-related cognitive impairment shows bi-directional association with dopamine receptor DRD1 and DRD2 polymorphisms in substance-dependent and substance-independent populations.
    Jacobs MM; Murray J; Byrd DA; Hurd YL; Morgello S
    J Neurovirol; 2013 Oct; 19(5):495-504. PubMed ID: 24078558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
    Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
    JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of psychiatric co-morbidity on cognitive functioning in a population-based sample of depressed young adults.
    Castaneda AE; Marttunen M; Suvisaari J; Perälä J; Saarni SI; Aalto-Setälä T; Aro H; Lönnqvist J; Tuulio-Henriksson A
    Psychol Med; 2010 Jan; 40(1):29-39. PubMed ID: 19413917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurocognitive functioning over the course of trauma-focused psychotherapy for PTSD: Changes in verbal memory and executive functioning.
    Nijdam MJ; Martens IJM; Reitsma JB; Gersons BPR; Olff M
    Br J Clin Psychol; 2018 Nov; 57(4):436-452. PubMed ID: 29717483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurocognitive impairment associated with predominantly early stage HIV infection in Abuja, Nigeria.
    Akolo C; Royal W; Cherner M; Okwuasaba K; Eyzaguirre L; Adebiyi R; Umlauf A; Hendrix T; Johnson J; Abimiku A; Blattner WA
    J Neurovirol; 2014 Aug; 20(4):380-7. PubMed ID: 24927825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.